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1. Introduction     
The global protein therapeutics market is approaching $100 billion in annual sales.  
Furthermore, the in vitro diagnostic market, which relies heavily on the use of recombinant 
proteins as analyte specific reagents, is approaching $50 billion in annual sales.  Increases in 
each market sector are estimated to be 8% to 20% per year for the next decade. Therefore, the 
costs of protein-based therapeutics and diagnostics will continue to be a significant 
percentage of health care expenses for patients and for agricultural animals and pets.   
A platform technology, which produces recombinant proteins at greatly reduced costs, 
provides inherent advantages, and allows low-tech sustainability of product lines, 
represents a competitive innovation which could create significant wealth in this industry.  
The use of soybean-derived proteins has the potential to provide such advantages.  Since the 
use of recombinant proteins is widespread in human and animal therapeutics and 
diagnostics, there are thousands of potential applications for such a platform technology.  
While no one technology is optimal for the expression of every transgenic protein (Brondyk, 
2009), the research that we have performed to date demonstrates the utility and feasibility of 
commercial applications for proteins made in transgenic soybean seeds.  
Soybean seeds expressing transgenic proteins represent a novel, sustainable platform 
technology which overcomes some of the current limitations for producing recombinant 
proteins for diagnostics, therapeutics, and industrial applications.  Advantages include low 
cost of glycoslyated protein production, greenhouse containment, highest protein/biomass 
ratio, marketable formulations which require no purification from soy, safety, accurate 
dosing, low cost of protein purification, low-tech sustainability of product lines, reduced 
risk of contamination, ease of scalability, minimal waste produced, as well as being a green 
technology.  To our knowledge, no other protein expression technology compares.  
Despite the fact that the present protein therapeutic and diagnostic markets are growing 
rapidly, some applications continue to be limited by the current technologies employed 
(Brondyk, 2009).  For example the cost of production and purification of certain recombinant 
proteins makes their use in particular applications non-profitable.  Some proteins cannot be 
expressed by any current technology and require expensive purification from human or 
animal tissues.  A platform technology which could alleviate these concerns would create 
significant opportunities for novel product development, or expanded applications for 
existing products.  In short, there is a need for alternative technologies for expressing and 
purifying recombinant proteins which can advance their applications. We propose that 
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soybean seeds expressing transgenic proteins represent a platform technology that can be a 
solution for many of these problems. Recent research provides a strong basis for this 
supposition. These results support the utility of this technology, have demonstrated its 
advantages, and suggest additional benefits that are currently being explored.   
2. Utility of glycosylated proteins produced in transgenic soybean seeds 
Roundup Ready soybeans were one of the first examples of a commercially viable 
transgenic plant (Padgette et al., 1995).  These transgenic soybeans express a functional 
enzyme, 5-enolpyruvylshikimate-3-phosphate synthase, making the plants tolerant to the 
herbicide, RoundupTM.  Presently, approximately 90% of the soybeans farmed in the United 
States are Roundup Ready. 
In addition to this value-added trait, there have been several recent successes in modifying 
soy crop lines aimed at imparting some commercial advantage.  Transgenic soybean lines 
expressing the cry1A gene provide protection against Lepidopteran species (McPherson & 
MacRae, 2009). Transgenic soybean lines expressing an active APase, demonstrated 
increased phosphorus content when grown in soils with limited phosphate content (Wang et 
al., 2009). Alterations in seed oil content have been achieved using transgenic soybean plants 
expressing genes having lysophosphatidic acid acyltransferase activity (Rao & Hildebrand, 
2009). Over-expression of an aspartate kinase in transgenic seeds allowed increased 
threonine levels to occur (Qi et al., 2010). While these examples are not a comprehensive 
listing of value-added traits that require the expression of a function enzymatic protein, they 
serve to demonstrate the amenability of soybean seeds to such transformations. 
While value-added traits are being exploited, transgenic soybean seeds have also been used 
as bioreactors to express a variety of foreign proteins. For example, Zeitlin, et al. (Zeitlin et 
al., 1998) successfully expressed functional antibodies against herpes simplex virus-2 
glycoprotein B in transgenic soybeans. More recently, proinsulin has been expressed and the 
storage vacuoles can accumulate mature polypeptide in these seed lines (Cunha et al., 2010).  
In our laboratories, we have successfully expressed the subunit protein antigens, E. coli, 
FanC (Garg et al., 2007; Oakes, Bost, & Piller, 2009; Piller et al., 2005), non-toxic, mutant 
forms of several bacterial toxins, and potential immunomodulatory proteins in transgenic 
soybean seeds, and are evaluating their usefulness as therapeutics. We have also 
successfully expressed particular full-length human proteins, and ongoing studies are aimed 
at demonstrating their substantial equivalence for use as analyte specific reagents in 
diagnostic assays.   
While this is not an exhaustive listing of the plant and foreign proteins which have been 
expressed in transgenic soybean seeds, these examples demonstrate the utility of this 
platform technology. There are several reasons for the success of such endeavors, but 
perhaps the most important lies in the biology of the soybean seed itself. One of the most 
important functions of the seed is to express and package proteins. This entails post-
translational modifications, including glycosylation, and packaging which not only allows 
proper folding, but also provides an environment for stable, long-term protein storage.  This 
conclusion is supported by the fact that many of the transgenic proteins expressed have 
enzymatic activity, ability to bind antigen, or the ability to be recognized by monoclonal 
antibodies specific for their native counterparts. 
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3. Soybean seeds represent the highest protein to biomass ratio  
Soybean seeds, by weight, are 40% protein with approximately 20% oil, 35% carbohydrates, 
and 5% ash (Liu, 1999).  Most of the normal soy seed proteins are heat-stable and desiccant-
resistant, in keeping with the ability of soybeans to remain germinate-capable following 
years of storage in ambient conditions.  Soybean plants can produce as much as twice the 
protein per acre of any other major crop (see: http://www.soyatech.com/soy_health.htm).  
Protein production by soy is also more efficient than animal-derived protein when factoring 
the acreage required for grazing or feeding.  As we will discuss below, this fundamental 
characteristic of soybean seeds to produce and store large amounts of protein may be 
exploited as a platform technology for expression. 
4. High yield translates into a potential for low cost protein production  
Present and future use of recombinant proteins will be limited in large part by their cost of 
production. Presently, the expense of expressing and purifying some recombinant proteins 
prohibits or limits their practical or realistic use. This is true for some therapeutic, as well as 
diagnostic, applications in westernized societies, and such barriers are even greater for 
developing countries. Unless this economic burden can be overcome, barriers for product 
development will remain.  For some applications, too much recombinant protein is needed 
such that the cost is prohibitive.  For some applications, elaborate purification schemes make 
particular proteins unaffordable. For some applications, there is no source of some 
recombinant proteins, requiring isolation from human or animal tissues. A platform 
technology which could alleviate these concerns would create significant opportunities for 
novel product development, or expanded applications for existing products, and therefore, 
create significant wealth. Decisions to develop commercial products which include such 
proteins will depend largely on the practicality of having a cost-sustainable platform 
technology. Theoretically, expression of transgenic proteins in soybean seeds represents one 
of the most cost-efficient platforms, and recent work has demonstrated potential economic 
advantages. 
Presently we (Garg, et al., 2007; Oakes, Bost, et al., 2009; Piller, et al., 2005), and others 
(Cunha, et al., 2010; Ding, Huang, Wang, Sun, & Xiang, 2006; Moravec, Schmidt, Herman, & 
Woodford-Thomas, 2007; Qi, et al., 2010; Rao & Hildebrand, 2009; Wang, et al., 2009; Zeitlin, 
et al., 1998), have developed stable soybean lines that express 1% to 4% of their total soluble 
protein as the transgenic protein.  Since soybean seeds are 40% protein by weight, an 
average sized seed weighing approximately 150 milligrams represents approximately 2.4 
milligrams of transgenic protein per seed at 4% expression (Table 1).  As will be discussed 
below, soybeans can easily be converted into soy powder, and, one liter of this powder 
totals approximately 800 grams of seed material.  At 4% expression, this one liter of soy 
powder contains approximately 12.8 grams of the unpurified, transgenic protein (Table 1).  
It is useful to compare this production with that for a liter of broth from bacterial (Zerbs, 
Frank, & Collart, 2009), yeast (Cregg et al., 2009), insect (Jarvis, 2009), mammalian (Geisse & 
Fux, 2009), or plant (Hellwig, Drossard, Twyman, & Fischer, 2004; Lienard, Sourrouille, 
Gomord, & Faye, 2007) cell culture.     
Since retail costs of commercially available recombinant proteins can easily be hundreds to 
thousands of dollars per milligram, extrapolations presented in Table 2 are enlightening.  One 
liter, or 800 grams, of soy powder could represent as much as 12.8 grams of transgenic protein 
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at an expression level of 4%.  As shown in Table 2, potentially, as little as one liter of total soy 
protein could contain the equivalent of millions of dollars of unpurified transgenic protein. 
 
Percent expression of the 
transgenic protein 
Milligrams of transgenic 
protein per seed (150 
milligrams) 
Grams of transgenic 
protein per liter (800 
grams of soy powder) 
1% 0.6 milligrams 3.2 grams 
2% 1.2 milligrams 6.4 grams 
4% 2.4 milligrams 12.8 grams 
8% 4.8 milligrams 25.6 grams 
Table 1. Estimated amounts of transgenic protein per seed or per one liter of soy powder 
 
Retail commercial cost of a theoretical 
recombinant protein per milligram 
Linear extrapolation of commercial value for 
12.8 grams of the theoretical recombinant 
protein 
$10 $128,000 
$100 $1,280,000 
$1000 $12,800,000 
$10,000 $128,000,000 
Table 2. Extrapolation of the potential value for one liter of soy protein powder expressing a 
particular transgenic protein at a level of 4% 
Further extrapolations can be made for bulk production of transgenic soybeans in secure 
greenhouses. Such greenhouses provide containment and controlled conditions which allow 
optimal growth for maximal yields. Using such conditions, it is not difficult to obtain 60 
bushels of soybeans per greenhouse acre (see http://www.soystats.com). The industry 
standard for an average weight of a bushel of soybeans is 60 pounds, with an average 
quantity of 2500 seeds per pound. This computes to approximately 9 million transgenic 
soybean seeds per acre. At an average weight of 150 milligrams per seed, this represents 
approximately 1,350 kilograms of seeds or 540 kilograms of total soy protein.  As shown in 
Table 3, at already achieved 4% expression levels, this calculates to 21.6 kilograms of 
transgenic protein per greenhouse acre. 
 
Percentage 
expression of the 
transgenic protein 
Average estimated quantity of 
soybean protein per greenhouse 
acre 
Calculated quantity of 
transgenic protein per 
greenhouse acre 
1% 540 kilograms total soy protein 
5.4 kilograms of transgenic 
protein 
2% 540 kilograms total soy protein 
10.8 kilograms of transgenic 
protein 
4% 540 kilograms total soy protein 
21.6 kilograms of transgenic 
protein 
8% 540 kilograms total soy protein 
43.2 kilograms of transgenic 
protein 
Table 3. Estimated quantities of transgenic protein per greenhouse acre based on percent 
expression 
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It should be noted that we have included 8% expression levels of the transgenic protein in 
Tables 1 and 3.  While we have yet to achieve such levels in our laboratory, the use of 
transgenic soybeans to express foreign proteins is evolving [e.g. (Schmidt & Herman, 2008)].  
Recent DNA sequencing of the soybean genome (Hyten et al., 2010; Schmutz et al., 2010), the 
development of better promoters, engineering of high protein-expressing seeds, and other 
coming advances, promise to further increase the efficiency of expression of transgenic 
proteins using this platform technology.  Therefore it seems reasonable to conclude that 
future advances will only facilitate our ability to increase the level of protein expression.  
While future advances promise even higher percentages of transgenic protein expression, 
current levels will permit contained greenhouse to produce bulk quantities of particular 
proteins.  Using theoretical costs for a recombinant protein as before, Table 4 extrapolates 
the potential value for an acre of greenhouse grown soybeans at an expression level of 4%.  
Again, these numbers serve to underscore the potential for high capacity of transgenic 
protein production using a confined growth space. 
 
Retail commercial cost of a 
theoretical recombinant 
protein per milligram 
Calculated quantity of 
transgenic protein per 
greenhouse acre at 
4% expression 
Linear extrapolation for the 
potential value of 21.6 
kilograms of the theoretical 
recombinant protein 
$10 
21.6 kilograms of transgenic
protein 
$216,000,000 
$100 
21.6 kilograms of transgenic
protein 
$2,160,000,000 
$1,000 
21.6 kilograms of transgenic
protein 
$21,600,000,000 
$10,000 
21.6 kilograms of transgenic
protein 
$216,000,000,000 
Table 4. Extrapolation of the potential value for an acre of greenhouse soybeans expressing a 
particular transgenic protein at a level of 4% 
5. Greenhouse containment for growing transgenic soybeans 
As shown in Tables 1, 2, 3, and 4, it is clear that at expression levels already obtained (e.g. 
1% - 4%) there will be little reason to grow such transgenic plants in open fields. At 
production levels of 3-10 kilograms per acre, and with the potential for 3 separate growing 
seasons per year, propagation in contained greenhouses would impart few limitations, even 
for bulk production. 
Despite the fact the soybean plant is self pollinating, secure greenhouse growth would 
provide additional containment by eliminating transgenic seed escape (Traynor, 2001).  As 
will be discussed below, processing of soybean seeds to soy powder can easily be 
accomplished in the greenhouse prior to removal of this non-germinating material for 
formulation and/or protein purification.  Such containment procedures, therefore, provide 
management of these genetically modified crops from release into the environment. 
Propagation of transgenic soybean plants in secure greenhouses also provides advantages in 
addition to containment.  Therapeutic and diagnostic proteins must be produced with good 
manufacturing practices (GMP) as dictated by approval agencies. Greenhouse growth 
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allows for ease of standard operating procedures to be implemented with respect to growth 
conditions, disease and pathogen monitoring, harvesting, and quality control. Stated simply, 
there are numerous advantages for greenhouse growth, and very few reasons for proposing 
open field propagation of transgenic soybean plants, that are destined to produce proteins 
for therapeutic and diagnostics purposes. 
6. Costs to grow an acre of transgenic soybeans in contained greenhouses 
The efficiency with which soybean plants can be grown in the field or in greenhouses is well 
documented (Traynor, 2001). This understanding of maximizing crop yields serves to 
reduce the cost of producing seeds from transgenic plants. Current costs per acre to plant 
and harvest soybeans from open fields range from $300 to $600 per acre depending upon 
planting conditions, treatments, geographic area, etc.  It has been estimated that greenhouse 
containment for soybean growth at Biosafety Level 2 (BSL-2) would increase this cost 
approximately 20 fold (Traynor, 2001). Despite this increased cost and the benefits that go 
with greenhouse production, the total expense for planting and harvesting remains a 
reasonable $6,000 to $12,000 per acre.  Based on these estimates, it is possible to project a cost 
per milligram for production and harvest of soybeans expressing a transgenic protein using 
BSL-2 conditions (Table 5).  
 
Percentage 
expression of the 
transgenic protein 
Calculated quantity of transgenic 
protein per greenhouse acre 
Costs per milligram of 
protein assuming $12,000 
production costs 
1% 
5.4 kilograms of transgenic 
protein 
$ 0.002 per milligram 
2% 
10.8 kilograms of transgenic 
protein 
$ 0.001 per milligram 
4% 
21.6 kilograms of transgenic 
protein 
$ 0.0005 per milligram 
8% 
43.2 kilograms of transgenic 
protein 
$ 0.00025 per milligram 
Table 5. Cost production projections per milligram of transgenic protein using BSL-2 
greenhouse conditions and assuming $12,000 per acre total production costs 
It is clear to see the potential for large scale production of transgenic proteins at a very low 
cost of production when one considers such calculations. 
7. Formulations which require no purification of the transgenic protein from 
soy 
The cost projections in Table 5 pertain only to the growth and harvesting of soybean seeds 
expressing the transgenic protein.  As with all protein expression systems, additional costs 
are required for purification of the protein of interest. However, before we discuss 
purification costs and the advantages of soybean-derived proteins, an intriguing possibility 
is the use of formulations made from transgenic soybean seeds which would require no 
purification of the protein prior to its use. 
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Soybeans can be formulated into a variety of consumables.  Simply grinding soybeans into a 
powder (e.g. soy powder) is sufficient for some agricultural purposes, including the 
addition to feedstocks. However soy powder is routinely solvent extracted to remove oils, 
followed by moist heat and drying to produce soybean meal, which can also be consumed. 
Other formulations include soy flour which is made from finely ground, defatted beans, 
followed by removal of solvents and drying. Perhaps the most recognizable formulation is 
soy milk where whole beans can be ground and mixed with heated water to produce this 
consumable product. These are just a few examples of the consumable formulations that can 
be made from soybeans, and serve as a starting point for discussing how such formulations 
might be useful in human therapeutics. 
Oral therapies with recombinant proteins have been suggested over the years. Some 
advantages of such therapies include the ease of administration, patient compliance, safety, 
and no requirement for medical personnel, among others. Some problems with oral protein 
therapy include the degradation of proteins as they pass through the gastrointestinal tract 
and the limited bio-availability to the blood stream and other organs. Despite these 
limitations, the advantages of oral therapies have spawned continued interest in commercial 
development by attempting to overcome the shortcomings using technological advances 
(Karsdal et al., 2010). 
Theoretically, formulations made from transgenic soybean seeds expressing a particular 
protein may represent one technological advance that can be applied to some oral 
therapeutics for human or agricultural use.  For discussion, consider the advantages of 
expressing a theoretical therapeutic protein in transgenic soybean seeds. The first 
consideration is purification. Bacterial, yeast, insect, mammalian, or plant culture 
technologies all require purification since the broth in which they propagate contain 
enumerable substances which must be removed before the protein can be deemed 
sufficiently safe to be consumed. Alternatively, the equivalent soybean-derived therapeutic 
protein would demand no purification. Soy formulations (e.g. soy powder, soy flour, soy 
milk, etc.) are consumed daily by billions of individuals and agricultural animals with few 
undue effects, and many health benefits (Messina, 1999; Slavin, 1991). Therefore, unless 
there is some compelling reason to purify a protein from soy, there would be no reason to 
suggest that oral therapeutic formulations made from transgenic beans would not be safe 
for consumption. Stated simply, purification of soybean-derived therapeutic proteins from 
soy is not, necessarily, a prerequisite for their use. 
Such a theoretical scenario becomes immediately untenable if the soybean-derived therapeutic 
protein is destroyed following formulation from beans to a consumable.  Recent success in our 
laboratory (Oakes, Bost, et al., 2009), and by others (Robic, Farinas, Rech, & Miranda, 2010), has 
demonstrated that a variety of formulations contain intact transgenic protein. While such 
empirical, stability studies will need to be performed with each particular transgenic protein, 
there are enumerable formulation strategies which have already been industrialized for soy 
consumables. Gentle versus more aggressive manipulations of soybeans have already been 
defined for their ability to maintain endogenous protein stability. Many of these manipulations 
are less egregious than those used during purification of recombinant proteins from bacterial, 
yeast, insect, mammalian, or plant cell culture broth expression systems. With such a diversity 
of formulations strategies already available for soy, identifying one which maintains 
transgenic protein stability seems likely. 
While individual soybean seeds from the same and different plants can vary somewhat in 
the level of transgenic protein expression, this variability is not a major concern when 
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developing therapeutic dosages. Soy formulations made from a lot of seeds can easily be 
blended into highly consistent mixtures. This is true for soy milk or soy powder 
formulations. Following homogenization, a given volume or weight would contain 
equivalent doses of the protein.  Furthermore, it would be easy to standardize different lots 
to an equivalent dose by the addition of wild type soy milk or soy powder. Therefore the 
ability to formulate large lots of transgenic seeds into homogenous mixtures alleviates 
concerns about variability in dosing.   
Labile proteins which are destroyed as they pass through the gastrointestinal tract make 
poor oral therapeutics.  However formulations made from transgenic soybeans may have 
some advantages in protecting the therapeutic protein while passing through the gut.  Soy 
milk formulations have inherent buffering capacity (Lutchman et al., 2006; Park, 1991), 
which helps to neutralize the acidic environment in the gastrointestinal tract.  Such acid-
neutralizing capacity of such formulations might aid in protein stability. Furthermore, 
current formulations made from transgenic soybean seeds would contain 1% to 4% of the 
therapeutic protein, leaving the remaining 96% to 99% protein as soy. These excess soy 
proteins in milk or powder formulations may facilitate the passage of proteins through the 
gut by competitively limiting protease activity.  Taken together, the inherent properties of 
soy formulations would likely provide some protection against degradation of the 
therapeutic protein following oral treatment.   
The composition of oral therapeutics is tightly regulated to assure that no significant level of 
toxins, harmful substances, or transmissible agents are present. Bacterial, yeast, insect, 
mammalian, or plant culture technologies all require purification since the broth in which 
they propagate contain enumerable substances which must be removed before the protein 
can be deemed sufficiently safe to be consumed. Alternatively, soy protein and soy milk 
formulations for infant, adult, and agricultural use are safe to consume and have significant 
nutritional benefit (Messina, 1999; Slavin, 1991).  In fact, soy formulations are so safe that 
they are routinely fed to infants with little side effects (Badger, Ronis, Hakkak, Rowlands, & 
Korourian, 2002; Motil, 2000; Seppo et al., 2005). Such widespread use suggests that 
therapeutic-containing soy formulations would not pose any significant risk, supporting the 
notion that transgenic soybean formulations would not require purification of the protein 
prior to treatment. While glycosylation of soybean-derived transgenic proteins will likely 
differ from human or animal glycosylation patterns (Liu, 1999), this too is unlikely to be 
problematic.  Glycosylation patterns of normal soy proteins will likely be similar to those 
glycoslyation patterns observed on the transgenic proteins since these post translational 
modifications will be carried out by the same cellular machinery.  If true, then humans and 
animals have been exposed to these particular glycosylation patterns in consumable soy 
formulations for a long time without undue effect.  Therefore there is little reason to believe 
that formulations derived from transgenic soybeans will contain any harmful substances 
which would preclude their use in oral therapies.  
One recent study (Oakes, Piller, & Bost, 2009) has demonstrated the safety of oral soy 
formulations.  While soy proteins themselves are considered safe, it was not altogether clear 
whether vaccine formulations which contain soy proteins combined with immune 
stimulating molecules would induce an anti-soy immune response. Using this mouse model, 
we found that no significant antibody response against soy could be detected, even when 
these animals were given soy protein formulations containing the oral adjuvant, cholera 
toxin. The likely reason for this outcome is that most animal chows contain soy protein as a 
significant ingredient.  In fact, these mice were consumed soy in their food chow throughout 
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their life, as is the case for many agricultural animals and most humans.  It is likely that 
these mice did not respond to soy proteins since it is a normal dietary constituent.  This 
study (Oakes, Piller, et al., 2009), therefore, demonstrated the safety of oral soy formulations, 
even when combined with immune stimulating agents.     
A final consideration for oral therapeutics is targeting the protein so that it is efficiently 
adsorbed from the gut, allowing therapeutic concentrations to be achieved in the target 
organ.  There have been many strategies for targeting (Lambkin & Pinilla, 2002), including 
the use of fusion proteins which effectively bind particular cells and facilitate passage from 
the lumen or binding to a target organ. Unfortunately, fusion proteins can be large in size 
and complex in their folding making some systems inappropriate or incapable of 
expressing.  As noted previously (see section 2), transgenic soybean seeds have been able to 
express large, complex proteins (Zeitlin, et al., 1998) which have binding characteristics.  
Therefore it seems likely that such fusion proteins which target cells and organs would be 
ideal candidates for this platform technology.  Once again, there would seem to be little 
advantage of purifying such fusion proteins from soy formulations prior to their use since 
targeting would likely be unaffected by the presence of native soy proteins.       
In summary, we have presented the intriguing possibility that it might be possible to use 
formulations made from transgenic soybean seeds containing a therapeutic protein without 
the need for prior purification.  In fact, there may even be some significant advantages of 
soy formulations. Taken together, an intriguing question for some soybean-derived oral 
protein therapeutics might be: Why purify? 
8. Soybean-derived proteins: the potential for simple, low cost protein 
production  
For most therapeutic and diagnostic applications, GMP-certified proteins will require 
purification.  Isolation schemes for such proteins can be fraught with technical challenges 
and regulatory oversight.  While concerns about the presence of transmissible agents, trace 
contaminants, and necessary additives to increase protein stability continue to mount, 
technological advances which minimize any of these concerns would represent true 
breakthroughs. The use of soybean formulations to overcome present limitations, and 
possibly eliminate the need for purification of transgenic proteins for some applications, 
may represent one such solution. 
When considering protein purification schemes, it is useful to examine the starting material 
from which the protein must be isolated. For those proteins which must be isolated from 
human or animal tissues or fluids, concerns about transmissible agents, complexity of the 
starting material, and variability of purity by suppliers exist. For bacterial expression, 
removal of toxins, and denaturation and renaturation requirements can be costly. For yeast, 
insect, mammalian, or plant cell culture broths, the complexity of the starting material and 
the high volume to protein biomass ratios can be problematic. Regardless of the starting 
material or expression system, a typical isolation of a desired protein requires removal of 
hundreds to thousands of irrelevant proteins and similar numbers of other contaminants. 
Conversely, soybean seeds contain a very limited number of protein species (Mooney, 
Krishnan, & Thelen, 2004; Natarajan, 2010).  Studies have estimated 40-50 different protein 
spots on 2D gel electrophoresis, with about half of these representing aggregates, subunits, 
or truncated forms of a few dominant soybean proteins (e.g. glycinin and conglycinin).  The 
ability to remove such a limited spectrum of soy proteins from the desired transgenic 
www.intechopen.com
 Soybean - Molecular Aspects of Breeding 
 
12 
protein would not seem to be a difficult task.  Furthermore, these endogenous soy proteins 
are the same for every transgenic soybean line regardless of the foreign protein being 
expressed.  Therefore it seems logical that once purification schemes are established for 
reference proteins with different physical properties (e.g. proteins with acidic versus basic 
isoelectric points), it will be possible to quickly adapt these standard operating procedures 
to new transgenic proteins.           
Due to the high quantity of transgenic protein per liter of soy powder (see Table 1), the 
starting biomass for protein purification is small and can be easily controlled.  This reduces 
the need for concentration and further aids in the initial steps of the purification procedure. 
In summary, the inherent simplicity of the soybean seed and its high protein to biomass 
ratio should lead to the development of straightforward and cost-effective standard 
operating procedures for the purification of transgenic proteins.    
9. Low-tech propagation and production reduces costs 
While technological advances have expanded the protein therapeutic and diagnostic 
markets, many of these achievements require significant facilities and expertise, and, 
therefore, increased costs. Production facilities are often highly specialized, and these 
buildings are expensive to maintain. Similar overhead is required for protein purification, 
where the low protein biomass of some expression systems dictates the quantities of 
material which must be processed. Contrast these requirements with those necessary for 
propagation of an acre of transgenic soybean plants.  BSL-2 greenhouses are cheap and easy 
to maintain (Traynor, 2001), relative to specialized buildings for recombinant protein 
production. Technical support for the agricultural care of soy plants and greenhouse 
harvesting of beans requires substantially less training and expertise than maintaining 
prokaryote or eukaryote cell cultures. Furthermore, the starting material for protein 
purification (e.g. soy powder) is easy to obtain, and has extended pre-processing storage 
times.  These characteristics are in stark contrast to the procedural and time constraints 
placed on harvesting cultured cells or media.    
Stocks of prokaryotic and eukaryotic cell lines expressing a particular recombinant protein 
must be maintained, and this low temperature storage requires significant equipment and 
oversight. Conversely, founder seed stocks of stably expressing transgenic soybean lines can 
be stored for years at room temperature or with refrigeration, and retain their ability to 
germinate if kept dry. This simplistic, low-tech method of maintaining stocks and lines 
reflects a fundamental characteristic of soybean seeds, and takes advantage of their ability to 
remain viable for long periods of time under ambient conditions.      
10. Reduced risk of contamination with toxins and transmissible agents  
Regulatory agencies require lots of therapeutic and diagnostic reagent proteins to be 
screened for the absence of a variety of toxins and transmissible agents. These include 
molecules like lipopolysaccharide and other bacterial contaminants, especially when 
prokaryotic expression systems are being used. For proteins isolated from human or animal 
tissues or cell expression systems, screening for the absence of transmissible agents (e.g. 
HIV, Hepatitis B, etc.) is an important quality control. The number and type of screenings 
will likely increase as the presence of prion proteins and other agents continue to be added 
to the list of possible contaminants. Screening for the absence of each of these toxins or 
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transmissible agents adds to the cost of production and increases possible product liability 
when these expression systems are used. 
Soybean-derived proteins pose little risk of spreading transmissible human or animal 
diseases. This is clear from the billions of infants, adults, and agricultural animals that 
routinely consume soy products. Screening for toxins or human or animal transmissible 
agents will likely be significantly less for lots of soybean-derived proteins.  In fact, any 
contaminants present in soybean-derived therapeutics or diagnostics would most likely be 
introduced during the purification process. Ultimately, this will reduce the cost of 
production and limit product liability for soybean-derived proteins.  
11. Waste disposal following production 
An increasing concern and cost-consideration for protein expression technologies is the 
amount and composition of waste produced during production. Regulatory requirements 
for decontamination and disposal of such waste into the environment add to the expense of 
production. This expense not only applies to the toxic byproducts produced, but to the 
equipment which is required. It is often more cost-efficient to replace machinery than 
attempt to clean and reuse it. It is highly likely that such waste disposal costs will only 
increase in the future. 
As transgenic soybean plants grow and mature, they proceed from vegetative stage to 
mature seed formation. As the vegetative plant dies, the seed matures, decreases its 
moisture content, and is then ready for harvesting. What remains after seeds have been 
extracted is non-germinating plant material. This material can easily be shredded, and for all 
intents and purposes is mulch. Stated simply, the environmental waste which requires 
decontamination prior to disposal for current expression systems will not be a significant 
cost consideration for soybean-derived proteins expressed using this platform technology. 
12. Ease of scaling  
Transgenic soybeans as a platform technology for protein expression provide a unique 
opportunity for scaling production. The only real limitation for dictating the magnitude of 
soybean-derived protein produced is the availability of BSL-2 greenhouse space. The 
production facilities available for expanding other culture-based expression systems are 
more costly and can be specialized. Such limitations threaten to increase future costs for 
conventional manufacturing.  Alternatively, the relative low cost of greenhouse construction 
and maintenance, the lack of geographical limitations for facility locations, and the low-tech 
requirements for production and propagation provide a compelling rational for expanding 
platform expression technologies to include transgenic soybeans.    
13. Long term soy powder storage: Uncoupling production and purification  
Expiration dates for therapeutics and diagnostic reagents are required by regulatory 
agencies.  The functional lifespan of proteins purified from any expression system depends 
largely upon the chemical nature of the particular protein itself, and upon the form in which 
that particular protein is prepared.  In general, labile proteins have shorter half-lives, and 
lyophilized preparations have longer expiration dates than proteins in aqueous solutions.  
To date, these characteristics have been some of the predominant limitations that increase 
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costs and require product replacement.  Unfortunately, once recombinant proteins are 
purified, they have the half-lives and expiration dates dictated by these chemical and 
physical properties.  
Stockpiling purified proteins can be a risky proposition if such products cannot be used 
prior to their expiration dates.  With most current expression technologies, the purification 
of a protein follows soon after the propagation of cells or cultures containing the desired 
protein. This necessitates coupling production to purification schemes in a limited time 
frame.  Problems with production or purification can result in the lack of available product.  
Alternatively, an exaggerated estimate of product need may lead to overstocked, expired 
product. 
Platform expression technologies which allow the processes of production and purification to 
be uncoupled would provide a significant advantage.  Consider the example of transgenic 
soybeans expressing a desired protein. A manufacturer could produce an excess of transgenic 
seeds and convert them to powder. At this point in production, the desired amount of soy 
powder could be taken for protein purification, while excess soy powder could easily be stored 
for months to years until needed.  If there were problems with protein purification, this excess 
soy powder would be immediately available.  If product demand had initially been 
underestimated, the excess powder could be used for protein purification forthwith. 
Cultivating an excess of transgenic soy allows stockpiling of seed material which could be 
used immediately or well into the future. Such flexibility adds significant value, since this low-
tech, long term storage of crude product allows for future use without delay.  In this manner, 
product expiration dates do not necessarily have to dictate production schedules.          
14. Stability of transgenic proteins in seeds and soy powder: Time  
One function of the soybean seed is to package and store proteins. This allows seeds to be 
dormant for years in ambient, dry conditions and still maintain the ability to germinate.  We 
anticipated that this fundamental property of soybean seeds would also allow transgenic 
proteins to be stable for years once expressed.   
A recent publication demonstrates that this is in fact the case for one model protein (Oakes, 
Bost, et al., 2009). Seeds were stored at room temperature and at ambient conditions for 
more than 4 years, and demonstrated no detectable degradation of the transgenic protein 
expressed in these seed lines.  We have yet to reach a time when seed-contained transgenic 
proteins have demonstrated significant degradation compared to their stability in newly 
harvested seeds if the aged seeds are kept dry. Similar results have been obtained when 
analyzing the stability of soy powder formulations contaning transgenic proteins.  While 
this first publication demonstrates the results for one model protein, we have since 
conducted studies in our laboratories to show stability for several additional transgenic 
proteins that were stored under ambient conditions for years (data not shown).  Such 
empirical studies will need to be performed with each new protein expressed.  However, the 
work performed to date suggests that an extended stability over time of transgenic proteins 
expressed in soybean seeds is a fundamental characteristic of this platform technology.    
15. Stability of transgenic proteins in seeds and soy powder: Formulations  
In the same publication (Oakes, Bost, et al., 2009), we demonstrated the ability to formulate 
transgenic soybeans into milk and powders without the destruction of the expressed 
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protein.  Varying combinations of heating, grinding, and solvent extractions were used to 
demonstrate the ability to formulate this model protein without degradation or destruction.  
It should be noted that the processes used in this work mimicked some industry standards, 
suggesting that manufacturing equipment and operating procedures already in place may 
be adapted for use. Furthermore, we have performed similar studies with other transgenic 
proteins and have had success in formulating them as well while maintaining stability (data 
not shown). Therefore, to date, a variety of procedures which formulate soybeans into 
consumables did not result in the destruction of the transgenic protein.  This property may 
not be true for every soy extraction procedure, and may not be true for every foreign protein 
expressed. However with the diversity of extraction methods available, it should be possible 
to tailor manufacturing toward optimal formulations.       
16. Stability of transgenic proteins in seeds and soy powder:  No cold chain 
requirement  
We have also demonstrated the ability of transgenic soy powder and milk to be shipped 
internationally at ambient temperatures without degradation of the protein (Oakes, Bost, et 
al., 2009). These studies not only demonstrate that refrigeration is unnecessary, but suggest 
that the process of production and protein purification can be uncoupled across continents. 
For example, production of transgenic seeds and processing to non-germinating powder 
might occur in one country. The soy powder could then be shipped internationally and 
stored until formulated or until the transgenic protein is isolated. Such a scenario would add 
manufacturing flexibility, and therefore value, for therapeutic and diagnostic proteins sent 
abroad. This should be especially true for emerging markets. The feasibility and success of 
such endeavors depends upon one fundamental property of the transgenic soybean seed; 
namely the ability to formulate, store, and ship material while maintaining protein stability 
without the requirement for cold storage.    
17. A green technology  
Safety concerns for recombinant protein expression technologies encompass not only 
product liabilities, but also the environmental impact of production. Oxygen consumption 
and the generation of toxic byproducts are becoming increasingly scrutinized when 
evaluating expression platforms.  Perhaps one of the most attractive attributes of transgenic 
soybeans as a platform for protein expression is that of being a green technology.  Growth of 
these plants consumes carbon dioxide and releases oxygen, which contrasts with most other 
prokaryotic and eukaryotic cell culture systems. Thus, the environmental-friendly 
production of proteins using this green technology is another inherent advantage of 
transgenic soybeans. 
18. Future directions  
Translation of transgenic soybeans as a platform technology toward commercialization is 
developing; however there are several hurdles which must be overcome. Standard operating 
procedures for growth, formulation, purification, and storage of soybean-derived powder, 
milk and purified proteins using GMP that are consistent with regulatory agency standards 
must be delineated.  In addition, product data for stability, expiration dates, purity, content 
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and substantial equivalence must also be defined.  Future success with these endeavors will 
be required to move this novel platform technology toward market acceptance, and 
ultimately to product commercialization. 
19. Conclusion  
Transgenic soybean seeds represent a unique platform for the expression and accumulation 
of a desired protein.  The advantages of this protein expression system stem from basic seed 
biology and their ability to express high levels of glycosylated protein for storage over time.  
For those applications which require high protein expression in a form that is stable in the 
environment at very low cost, transgenic soybean seeds provide significant advantages.   
As protein expression technologies expand and evolve, a consideration of the optimal 
platform for each protein produced seems sensible.  Transgenic soybean seeds represent an 
emerging technology with significant advantages for expressing some recombinant proteins. 
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